Achaogen (NASDAQ:AKAO)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a report issued on Wednesday. They currently have a $14.00 target price on the biopharmaceutical company’s stock. Guggenheim’s price target indicates a potential upside of 25.56% from the company’s previous close.

Several other equities research analysts have also issued reports on AKAO. Mizuho reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Achaogen in a research note on Thursday, September 28th. Leerink Swann reaffirmed an “outperform” rating and issued a $22.00 price objective (down previously from $28.00) on shares of Achaogen in a research note on Monday, October 9th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Achaogen in a research note on Thursday, November 9th. Stifel Nicolaus reduced their price objective on shares of Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, November 9th. Finally, Zacks Investment Research lowered shares of Achaogen from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $25.62.

Achaogen (NASDAQ AKAO) traded down $0.29 during mid-day trading on Wednesday, hitting $11.15. 1,135,500 shares of the company traded hands, compared to its average volume of 2,070,250. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99. Achaogen has a 1-year low of $10.24 and a 1-year high of $27.79. The firm has a market cap of $472.69, a price-to-earnings ratio of -3.32 and a beta of 1.35.

Achaogen (NASDAQ:AKAO) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The business had revenue of $0.58 million during the quarter, compared to analyst estimates of $2.09 million. During the same period in the previous year, the firm posted ($0.41) EPS. The firm’s revenue for the quarter was down 96.4% on a year-over-year basis. sell-side analysts anticipate that Achaogen will post -3.06 earnings per share for the current fiscal year.

In other news, major shareholder Robert W. Duggan bought 15,000 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was purchased at an average price of $10.89 per share, with a total value of $163,350.00. Following the transaction, the insider now directly owns 5,617,752 shares in the company, valued at $61,177,319.28. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Robert W. Duggan bought 50,000 shares of the business’s stock in a transaction on Friday, January 5th. The shares were purchased at an average cost of $11.51 per share, with a total value of $575,500.00. Following the transaction, the insider now owns 5,617,752 shares in the company, valued at $64,660,325.52. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 160,012 shares of company stock valued at $1,796,334. Company insiders own 8.36% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. raised its position in shares of Achaogen by 55.7% during the third quarter. Point72 Asset Management L.P. now owns 2,255,899 shares of the biopharmaceutical company’s stock valued at $35,982,000 after buying an additional 806,899 shares during the last quarter. State Street Corp raised its position in shares of Achaogen by 302.6% during the second quarter. State Street Corp now owns 1,677,097 shares of the biopharmaceutical company’s stock valued at $36,444,000 after buying an additional 1,260,509 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Achaogen by 32.2% during the second quarter. Vanguard Group Inc. now owns 1,410,129 shares of the biopharmaceutical company’s stock valued at $30,641,000 after buying an additional 343,428 shares during the last quarter. TimesSquare Capital Management LLC raised its position in shares of Achaogen by 25.1% during the third quarter. TimesSquare Capital Management LLC now owns 1,361,665 shares of the biopharmaceutical company’s stock valued at $21,719,000 after buying an additional 273,365 shares during the last quarter. Finally, Farallon Capital Management LLC raised its position in shares of Achaogen by 16.0% during the second quarter. Farallon Capital Management LLC now owns 948,500 shares of the biopharmaceutical company’s stock valued at $20,611,000 after buying an additional 131,000 shares during the last quarter. 85.74% of the stock is owned by hedge funds and other institutional investors.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/guggenheim-reiterates-buy-rating-for-achaogen-akao/1801244.html.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.